Zelgen(SH:688266) Xin Lang Cai Jing·2025-09-09 05:43Core Viewpoint - Zai Lab's stock price has shown significant growth this year, with a notable increase in trading activity and a mixed financial performance in the first half of 2025 [1][2]. Group 1: Stock Performance - On September 9, Zai Lab's stock price decreased by 2.09%, trading at 115.38 CNY per share with a total transaction volume of 350 million CNY and a market capitalization of 30.542 billion CNY [1]. - Year-to-date, Zai Lab's stock has risen by 85.17%, with a 7.63% increase over the last five trading days, 6.06% over the last twenty days, and 0.55% over the last sixty days [1]. Group 2: Financial Performance - For the first half of 2025, Zai Lab reported a revenue of 376 million CNY, representing a year-on-year growth of 56.07%, while the net profit attributable to shareholders was -72.8035 million CNY, a decrease of 9.42% compared to the previous period [2]. Group 3: Shareholder Information - As of June 30, 2025, Zai Lab had 8,795 shareholders, an increase of 16.75% from the previous period, with an average of 30,097 circulating shares per shareholder, down 14.35% [2]. - Notable institutional shareholders include China Europe Medical Health Mixed A and others, with changes in their holdings reflecting varying investment strategies [2].